101 related articles for article (PubMed ID: 24666252)
21. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
[TBL] [Abstract][Full Text] [Related]
22. In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
Krupar R; Schreiber C; Offermann A; Lengerke C; Sikora AG; Thorns C; Perner S
Leuk Lymphoma; 2018 Oct; 59(10):2493-2496. PubMed ID: 29431550
[No Abstract] [Full Text] [Related]
23. Immunophenotyping of acute leukaemias.
Béné MC
Immunol Lett; 2005 Apr; 98(1):9-21. PubMed ID: 15790504
[TBL] [Abstract][Full Text] [Related]
24. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia.
Retnakumari A; Jayasimhan J; Chandran P; Menon D; Nair S; Mony U; Koyakutty M
Nanotechnology; 2011 Jul; 22(28):285102. PubMed ID: 21654031
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia.
Orfao A; Vidriales B; Gonzalez M; Lopez-Berges MC; del Cañizo MC; San Miguel JF
Recent Results Cancer Res; 1993; 131():369-79. PubMed ID: 8210655
[No Abstract] [Full Text] [Related]
26. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens.
Syrjälä M; Anttila VJ; Ruutu T; Jansson SE
Leukemia; 1994 Sep; 8(9):1564-70. PubMed ID: 7522295
[TBL] [Abstract][Full Text] [Related]
27. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic findings in acute biphenotypic leukaemia.
Carbonell F; Swansbury J; Min T; Matutes E; Farahat N; Buccheri V; Morilla R; Secker-Walker L; Catovsky D
Leukemia; 1996 Aug; 10(8):1283-7. PubMed ID: 8709632
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia with concomitant expression of T-/B-lymphoid antigens and immunogenotypic alterations exhibiting t(7;12)(q32;q24).
Kawakubo K; Ohyashiki K; Ohyashiki JH; Kuriyama Y; Iwabuchi A; Kimura N; Sugita K; Nakazawa S; Toyama K
Leukemia; 1993 Jun; 7(6):909-11. PubMed ID: 7684801
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
31. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
Liu YR; Zhu HH; Ruan GR; Qin YZ; Shi HX; Lai YY; Chang Y; Wang YZ; Lu D; Hao L; Li JL; Li LD; Jiang B; Huang XJ
Leuk Res; 2013 Jul; 37(7):737-41. PubMed ID: 23601747
[TBL] [Abstract][Full Text] [Related]
32. Relation of some cytochemical activities to the expression of CD34 marker in acute leukemia.
Klobusická M; Babusíková O; Hrivnáková A
Neoplasma; 1993; 40(5):309-14. PubMed ID: 7505888
[TBL] [Abstract][Full Text] [Related]
33. Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?
Martin F; Apetoh L; Ghiringhelli F
Trends Mol Med; 2012 Dec; 18(12):742-9. PubMed ID: 23083809
[TBL] [Abstract][Full Text] [Related]
34. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.
Clayton A; Al-Taei S; Webber J; Mason MD; Tabi Z
J Immunol; 2011 Jul; 187(2):676-83. PubMed ID: 21677139
[TBL] [Abstract][Full Text] [Related]
35. Differential modulation of immune recognition molecules by interleukin-7 in human acute leukaemias.
Costello RT; Mallet F; Chambost H; Sainty D; Gastaut JA; Olive D
Eur Cytokine Netw; 1999 Mar; 10(1):87-96. PubMed ID: 10210778
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation.
Théâtre E; Frederix K; Guilmain W; Delierneux C; Lecut C; Bettendorff L; Bours V; Oury C
J Immunol; 2012 Aug; 189(4):1966-74. PubMed ID: 22802412
[TBL] [Abstract][Full Text] [Related]
37. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
[TBL] [Abstract][Full Text] [Related]
38. ENTPD1/CD39 is a promising therapeutic target in oncology.
Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
40. Immunophenotype of acute myeloid leukemia: correlation with morphological characteristics and therapy response.
Sperling C; Seibt-Jung H; Gassmann W; Komischke B; Sauerland C; Hiddemann W; Löffler H; Büchner T; Thiel E; Ludwig WD
Recent Results Cancer Res; 1993; 131():381-92. PubMed ID: 8210656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
